Test Price
130 AED✅ Home Collection Available
Newborn Screening Panel 4 (Inborn Errors of Metabolism) – 130 AED – DHA Approved
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO‑accredited processing (FEIA with confirmatory LC‑MS/MS).
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection – available daily 8 AM–11 PM.
Clinical Guidance: Telephonic post‑test interpretation by a DHA‑licensed General Practitioner.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Corporate Lab: DNA Labs UAE | DHA Facility License: 1143
Test Overview & Methodology
The Newborn Screening Panel 4 (NBS Panel 4) is a preventive health test that screens for 30+ inborn errors of metabolism using a single heel‑prick capillary blood sample. It detects life‑threatening yet treatable metabolic disorders – including phenylketonuria, maple syrup urine disease, and medium‑chain acyl‑CoA dehydrogenase deficiency – enabling early intervention and improved long‑term outcomes.
| Feature | DNA Labs UAE NBS Panel 4 | Standard Hospital Screening |
|---|---|---|
| Precision & Sensitivity | 99.9% via FEIA + confirmatory LC‑MS/MS | Variable; often 85–92% |
| Methodology | Fluoroimmunoassay (FEIA) & Specialized Immunoassays | Basic immunoassay or manual technique |
| Turnaround Time | Next day (Mon–Fri by 9 AM) | 3–5 working days |
Physician Insight & Safety Protocols
“As a practicing General Practitioner, I emphasize that newborn screening is a screening, not a diagnostic test. Abnormal results must be followed by confirmatory testing and clinical evaluation. Early detection via this panel allows for dietary or medical management that can prevent severe disability.” – Dr. Ajay Singh, DHA License: 36234132
Safety Advisory
Never discontinue any prescribed medication for the newborn without consulting the attending physician. The screening test is non‑therapeutic and does not replace clinical judgment.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Preterm infants (<34 weeks) or those who received blood transfusion within 72 hours – results may be unreliable.
- Exclusion: Incomplete sample (less than 3 blood spots) or improper drying – specimen will be rejected.
- Red Flag: Seek emergency care if your newborn shows lethargy, poor feeding, vomiting, seizures, or unusual odour.
- Red Flag: Rapid breathing, hypothermia, or jaundice appearing within 24 hours of birth requires immediate medical attention.
Patient FAQ & Clinical Guidance
1. What disorders are included in the Newborn Screening Panel 4?
The panel covers 30+ inborn errors of metabolism, including phenylketonuria, maple syrup urine disease, and medium‑chain acyl‑CoA dehydrogenase deficiency. Additional conditions screened include congenital hypothyroidism, congenital adrenal hyperplasia, galactosemia, and biotinidase deficiency. The test targets aminoacidopathies, organic acidurias, and fatty acid oxidation disorders that can lead to intellectual disability or sudden death if untreated.
2. How is the sample collected for the newborn screening test?
A few drops of blood are taken from the baby’s heel onto a special filter paper card, which is then sent under temperature‑controlled conditions to the lab. The procedure is minimally invasive and performed by a trained pediatric phlebotomist, available through our VIP Mobile Phlebotomy service. The filter paper must have three fully filled circles of blood, properly dried, and accompanied by clinical details and drug history. Samples must be kept at 2–8 °C during transport.
3. When will I receive the newborn screening results?
Results are reported the next day if the sample is collected Monday through Friday by 9 AM, with same‑day telephonic guidance available. Reports are securely emailed and accessible in our online portal. Abnormal results trigger an immediate call from our clinical team, and we coordinate referrals to pediatric metabolic specialists if needed. Late or weekend collections are processed on the next working day.
UAE Regulatory & Data Privacy Adherence
Data Protection: This service complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning the Use of Information and Communication Technology in Health Fields. All patient data is handled with strict confidentiality.
Clinical Safety: Patient consent and clinical safety are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Laboratory Accreditation: DHA Facility License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. All home collections are performed by DHA‑licensed phlebotomists.
Clinical & Logistical Metadata
| Test Name | Newborn Screening Panel 4 (Inborn Errors of Metabolism) |
| Price (AED) | 130 |
| Turnaround Time | Next day (Mon–Fri by 9 AM) |
| Sample Type / Matrix | Capillary blood (heel prick) on filter paper |
| Methodology Used | Fluoroimmunoassay (FEIA) with confirmatory LC‑MS/MS |
| ICD‑10‑CM Code | E70.0, E71.0, E71.3 |
| LOINC Code | 57711-2 |
| DHA Facility License & Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians